While MMR‐deficient CRC may have a more favourable stage‐matched prognosis compared to MMR‐proficient tumours [32], they are also relatively resistant to 5‐fluorouracil‐based chemotherapy [33]. This evidence concerns the gene MRC1 and neoplasm.